September 20, 2017
Edinburgh, UK

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).

The use of Synpromics’ synthetic promoters will enable the enhancement of Solid Biosciences’ investigational gene therapy candidates for the treatment of DMD. These muscle-selective promoters have been designed using Synpromics’ PromPTÒ technology and bioinformatics expertise, and will be evaluated by Solid Biosciences for optimal product specific gene control.

“We are excited to leverage our PromPTÒ technology platform to generate promoter candidates closely matching the precise criteria and specific product requirements for Solid Biosciences’ muscle gene medicine programme in Duchenne,” David Venables, CEO of Synpromics, commented. “The collaboration between the scientific teams will enable the effective and rapid in vivo evaluation of the candidate promoters as compared to industry standards.”

“Synpromics’ cutting-edge technology has the potential to enhance our gene therapy development efforts, helping us to fulfil our promise to bring meaningful therapies to all patients with this devastating disease,” said Joel Schneider, PhD, Chief Technology Officer, Head of Exploratory R&D at Solid Biosciences. “This type of collaboration is key for building our next-generation gene therapy portfolio as we focus on enhancing fundamental aspects of our gene delivery and protein expression capabilities.”

Duchenne muscular dystrophy (DMD) is a genetic muscle-wasting disease that is progressive, irreversible and ultimately fatal. DMD affects approximately one in every 3,500 to 5,000 live male births. Symptoms of DMD usually manifest between three to five years of age. As the disease progresses, patients are typically wheelchair-bound by their early teens and succumb to respiratory or heart failure in early adulthood. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory treatments. This research collaboration will help advance Solid’s programme to develop optimal product candidates for the company’s AAV muscle-directed gene therapy research programme.

Ends

For further information, contact:

Corporate Contact:

Dr. David Venables, CEO Synpromics Ltd

T: +44 (0)7825 323439

E: David.Venables@synpromics.com

PR Contact:

Deborah Cockerill / Emma Pickup

Sciad Communications Ltd

T: +44 (0)20 7470 8801

E: synpromics@sciad.com

Notes to Editors

About Synpromics

Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The company has developed PromPTÒ, its multi- dimensional bioinformatics database that enables productspecific  promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Adverum, uniQure, AGTC, GE Healthcare, Homology Medicines, Inc and Sartorius-Stedim Cellca as well as numerous undisclosed partners in the pharmaceutical sector.

About Synthetic Promoters

Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented.

For more information visit www.synpromics.com

Related news

Jan30

Solid Biosciences Inc. (NASDAQ:SLDB), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of $16.00 per share.

Jan25

Solid Biosciences Inc. (NASDAQ:SLDB) today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share, for total gross proceeds of approximately $125,000,000.

Nov30

Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.

Jul27

New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development

Jun07
  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.
May11

Solid Biosciences to Initiate Clinical Program for Gene Therapy Candidate in Coming Months

Mar30

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.

Mar14

Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.

Jan30

As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.

Pages

More information about Solid?

Please subscribe to receive our latest news